These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36438807)

  • 1. Potential safety signal of pregnancy loss with vascular endothelial growth factor inhibitor intraocular injection: A disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System.
    Sakai T; Mori C; Ohtsu F
    Front Pharmacol; 2022; 13():1063625. PubMed ID: 36438807
    [No Abstract]   [Full Text] [Related]  

  • 2. Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS).
    Ma P; Pan X; Liu R; Qu Y; Xie L; Xie J; Cao L; Chen Y
    Front Pharmacol; 2022; 13():1017889. PubMed ID: 36467087
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular and Cerebrovascular Adverse Events Associated with Intravitreal Anti-VEGF Monoclonal Antibodies: A World Health Organization Pharmacovigilance Study.
    Yang JM; Jung SY; Kim MS; Lee SW; Yon DK; Shin JI; Lee JY
    Ophthalmology; 2025 Jan; 132(1):62-78. PubMed ID: 39004231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis.
    Zhao X; Wu J; Zhu S
    Br J Clin Pharmacol; 2023 Feb; 89(2):458-469. PubMed ID: 35973681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.
    Shirani A; Cross AH; Stuve O
    Ther Adv Neurol Disord; 2024; 17():17562864241241383. PubMed ID: 38566910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
    Jedlowski PM; Jedlowski MF; Fazel MT
    Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
    Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
    Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy Loss Signal from Prostaglandin Eye Drop Use in Pregnancy: A Disproportionality Analysis Using Japanese and US Spontaneous Reporting Databases.
    Sakai T; Mori C; Koshiba H; Yuminaga R; Tanabe K; Ohtsu F
    Drugs Real World Outcomes; 2022 Mar; 9(1):43-51. PubMed ID: 34797554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pattern of adverse events induced by aflibercept and ranibizumab: A nationwide spontaneous adverse event reporting database, 2007-2016.
    Ha D; Choi SR; Kwon Y; Park HH; Shin JY
    Medicine (Baltimore); 2019 Aug; 98(33):e16785. PubMed ID: 31415382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
    Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reporting of Drug-Induced Myopathies Associated with the Combination of Statins and Daptomycin: A Disproportionality Analysis Using the US Food and Drug Administration Adverse Event Reporting System.
    Wei C; Yin W; He Z; Wu B
    J Clin Med; 2023 May; 12(10):. PubMed ID: 37240654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive signal detection of delirium-associated medication using the Food and Drug Administration Adverse Event Reporting System.
    Hatano M; Sogawa R; Shin K; Esumi S; Ishikawa A; Mizumura R; Araki H; Yamada S
    Gen Hosp Psychiatry; 2024; 90():50-55. PubMed ID: 38941744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system.
    Wu Z; Zhou P; He N; Zhai S
    Front Cardiovasc Med; 2022; 9():966331. PubMed ID: 36352852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Moreland-Head LN; Coons JC; Seybert AL; Gray MP; Kane-Gill SL
    J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):341-348. PubMed ID: 33403858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports.
    Sultana J; Scondotto G; Cutroneo PM; Morgante F; Trifirò G
    Front Pharmacol; 2020; 11():315. PubMed ID: 32226387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Fusaroli M; Giunchi V; Repaci A; Pelusi C; Mollica V; Massari F; Ardizzoni A; Poluzzi E; Pagotto U; Di Dalmazi G
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230533
    [No Abstract]   [Full Text] [Related]  

  • 20. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.